Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal A, C, W, Y tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Meningococcal A, C, W, Y tetanus toxoid conjugate vaccine** is a quadrivalent conjugate vaccine that provides active immunization against invasive disease caused by *Neisseria meningitidis* of serogroups A, C, W, and Y. It consists of purified capsular polysaccharides from these serogroups covalently linked to a tetanus toxoid protein carrier, which enhances the immune response by inducing T-cell dependent immunity. The primary indication is prevention of invasive meningococcal disease. The vaccine induces production of IgG, IgM, and IgA against the capsular polysaccharides, providing bactericidal protection. It is licensed for both children and adults, and clinical studies show robust immunogenicity and an acceptable safety profile. Tetanus toxoid conjugation offers potential for longer-lasting immunity, especially compared with unconjugated polysaccharide vaccines[1][2][3][4][5].
- Brand names
- MenQuadfiNimenrix
- Other names
- MenACWY-TTquadrivalent meningococcal tetanus toxoid conjugate vaccinemeningococcal groups A, C, Y and W-135 polysaccharide tetanus toxoid conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal A, C, W, Y tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal A, C, W, Y tetanus toxoid conjugate vaccine.